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OBJECTIVE — To determine the association between circulating soluble receptor for ad-
vanced glycation end products (sRAGE) and coronary atherosclerosis.
RESEARCH DESIGN AND METHODS — Using data from the Dallas Heart Study, a
probability-based population sample, the association between plasma levels of sRAGE and
coronary artery calcium (CAC) was assessed among 2,571 subjects with complete imaging and
sRAGE data.
RESULTS — AninversegradedassociationwasobservedbetweensRAGEquartilesandCAC,
with CAC prevalence of 28.5% in quartile 1 compared with 15.7% in quartile 4 (P  0.0001).
After multivariable adjustment, the associations between sRAGE levels in the ﬁrst and second
quartiles (versus fourth quartile) and CAC remained statistically signiﬁcant (adjusted odds ratio
1.71 [95% CI 1.2–2.4] and 1.5 [1.0–2.1], respectively).
CONCLUSIONS — sRAGE is a novel biomarker that is inversely associated with coronary
atherosclerosis. The role of sRAGE in the pathobiology of atherosclerosis and its potential
prognostic and therapeutic implications warrant further investigation.
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T
he transmembrane receptor for ad-
vanced glycation end products
(RAGE), expressed on a variety of
cells including endothelial, smooth mus-
cle, and mononuclear cells, binds ad-
vanced glycation end products and other
proinﬂammatory ligands and modulates
activity of several prothrombotic and
proinﬂammatory mediators (1,2). Results
from animal models provide evidence
supporting a role for ligand-RAGE bind-
ing in the development and progression
of atherosclerosis (3–5).
A circulating isoform of RAGE, solu-
ble RAGE (sRAGE), has been identiﬁed
(6,7) and theorized to competitively in-
hibit transmembrane RAGE-ligand bind-
ing, thereby attenuating atherosclerosis
(3–5). This hypothesis has been sup-
ported by animal experiments, where ad-
ministration of sRAGE to mouse models
retarded the progression of atherosclero-
sis (3–5).
Few human studies have been per-
formed evaluating the association be-
tween circulating sRAGE and human
atherosclerosis (8,9). The objective of
the present study was to determine the
association between sRAGE and
atherosclerosis.
RESEARCH DESIGN AND
METHODS— The Dallas Heart Study
is a probability-based population sample
of adults living in Dallas County with in-
tentional oversampling of black subjects.
A detailed study design and variable def-
initions have previously been published
(10); subjects were recruited from July
2000 to January 2002. The present study
comprises 2,571 subjects with complete
sRAGE and coronary artery calcium
(CAC) data. Cardiac electron-beam com-
puted tomography scanning was per-
formed using an Imatron C-150XP
scannerwith3-mmslices;duplicatescans
were performed within 2 min. The Agat-
ston method was used to determine CAC
scores and recorded them as the average
of the two scans. Because of skewness,
CAC was analyzed as a categorical vari-
able, with prevalent CAC deﬁned by a
score 10, a data-derived threshold that
optimizesthesignal-to-noiseratiotomin-
imize false-positive rates (11).
Venous blood was collected into
EDTA tubes and centrifuged for 1,430g
for15minat4°C.Theplasmacomponent
was stored at 80°C. Immunoassays for
sRAGE were performed in 384-well mi-
crotiter plates on thawed frozen plasma
samples at Biosite (San Diego, CA). The
sRAGE assay was a sandwich ELISA with
a minimum detection limit of 0.11 ng/ml.
Intra- and interassay coefﬁcients of varia-
tion ranged from 6.4 to 8.3% at sRAGE
levels of 1.2 and 31.2 ng/ml, respectively.
For analyses, subjects were divided into
quartiles of sRAGE. Univariable and mul-
tivariable logistic regression analyses,
with adjustment for traditional athero-
sclerosis risk factors, were performed to
determine associations between sRAGE
quartiles and CAC; additional analyses
were performed evaluating sRAGE as a
continuous variable using a logarithmic
transformation of sRAGE levels. Crude
and adjusted odds ratios are presented
with 95% CIs. Probability values of
0.05 were considered statistically sig-
niﬁcant. The study protocol was ap-
proved by the University of Texas
Southwestern Medical Center institu-
tional review board. All participants pro-
vided written informed consent.
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10 years, with 69% nonwhite subjects
and 56% women. Levels of sRAGE were
inverselyassociatedwithanumberofrisk
factors, including increasing age, diabe-
tes, hypertension, smoking, and meta-
bolic syndrome; compared with white
and Hispanic subjects, blacks had signif-
icantly lower median sRAGE values.
There was a graded, stepwise, inverse
association between CAC prevalence and
increasingquartileofsRAGE,from28.7%
in the ﬁrst quartile (lowest sRAGE levels)
to 15.4% in the fourth quartile (P 
0.0001;Fig.1).Inmultivariableanalyses,
an independent association remained be-
tween an sRAGE values in quartiles 1 and
2comparedwithvaluesinquartile4(Fig.
1). Analyzed as a continuous variable us-
ing log-transformation of sRAGE, the as-
sociation with CAC remained statistically
signiﬁcant in a multivariable model.
The inverse associations between
sRAGE and prevalent CAC were qualita-
tively similar across selected subgroups
stratiﬁed by diabetes status, metabolic
syndrome status, and race (data not
shown).
CONCLUSIONS — The principal
novel observation of the present study is
that lower levels of sRAGE are indepen-
dently associated with a greater preva-
lence of coronary atherosclerosis,
demonstratedinalargeprobability-based
population study. These associations re-
mained statistically signiﬁcant after mul-
tivariable adjustment and were evident in
the overall population as well as across
several key subgroups. Because of small
sample sizes in some subsets, validation
of the ﬁndings in additional studies is
neededinkeysubgroups,includingthose
with diabetes.
Our observations are concordant
with the limited data investigating the re-
lationship between circulating sRAGE
and atherosclerosis (8,9). In a small co-
hort of nondiabetic Italian men, Falcone
et al. (8) demonstrated that subjects with
angiographic coronary artery disease had
lower levels of sRAGE than age-matched
control subjects without coronary artery
disease. Also, Koyama et al. (9) showed
that sRAGE was inversely associated with
carotid intima-medial thickness. Al-
though both studies are provocative, they
are limited by small sample sizes and the
discrete populations studied. These re-
ports coupled with the present results
providecompellingsupportforapossible
link between sRAGE and atherosclerosis.
Indeed, our observations lend valida-
tion to prior experimental observations
supporting the plausible contribution of
sRAGE to the development and progres-
sion of atherosclerosis (3,4). These con-
cordant observations are promising and
should prompt further evaluation of the
sRAGE/RAGE pathway to better under-
standthepathobiologyandtoexplorethe
potential of this pathway as a novel target
for the prevention and treatment of vas-
cular disease. The cross-sectional design
of our study allows only a demonstration
of association, and conclusions cannot be
drawn regarding causality. However, evi-
dence from several elegant animal studies
demonstrates that exogenous administra-
tion of sRAGE suppresses the progression
of atherosclerosis (3–5). Therefore, either
exogenous administration of sRAGE or
therapies that amplify endogenous
sRAGElevelsmayofferanattractivepath-
way to treat or prevent vascular disease
(12). Future investigation into sRAGE
modulation as a therapeutic modality is
needed.
In summary, within a large multieth-
nic population, we observed an indepen-
dent and graded association between
lower sRAGE levels and coronary athero-
sclerosis;therefore,sRAGEcouldproveto
beausefulbiomarkerforthepredictionof
atherosclerosis and cardiovascular dis-
ease risk. External validation of our data
inotherpopulations,especiallyincohorts
with cardiovascular outcomes, is crucial.
Withthedatafrompriorbasicscienceex-
periments and our hypothesis-generating
data, sRAGE appears to hold promise not
only as a biomarker for atherosclerosis
prediction but also as a potential thera-
peutic target for the treatment and pre-
vention of atherosclerosis and should be
investigated further.
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